Our Incyte Biosciences Iberia Team

When Incyte was born more than 20 years ago, we had a clear goal in mind: to improve the lives of patients through science, regardless of the magnitude of the disease, by finding new solutions for rare and difficult-to-treat diseases, and by pioneering the application of new treatments.

The COVID-19 pandemic has taught us that through science and research, great results can be achieved in a short time. This purpose, to help patients through science, has always been our inspiration. When I joined this project with the arrival of Incyte in Portugal in 2016, I knew that Incyte Biosciences Iberia represented an immense opportunity for the development of innovative therapies in unmet medical areas.

Since then, we have invested more than €61 million in research, development and innovation (R&D), reflecting our commitment to seek innovative solutions that improve patient health through research in Iberia. The Iberian innovation ecosystem is first class, and we are committed to strengthening it through collaboration to improve accessibility to our medicines in a sustainable manner.

Despite the difficulties of recent years, research remains an absolute priority for Incyte, and will continue to be so in order to meet the objective of continuing to innovate to improve the lives of patients.

Juan Diaz,

Associate Vice President, General Manager, Iberia